Headline News about Incyte Corp
![](https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-1024x576.png)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.png?width=1200&height=800&fit=crop)
Expert Ratings for Incyte
December 13, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/12/12/medicine-257349_12803.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/Businessman-Looking-MagnifyingGlass-Shut_0.jpeg?width=1200&height=800&fit=crop)
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets
December 07, 2023
Via Benzinga
Topics
Stocks
Exposures
US Equities
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.jpeg?width=1200&height=800&fit=crop)
The Latest Analyst Ratings for Incyte
November 21, 2023
Via Benzinga
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://cdn.benzinga.com/files/images/story/2023/11/21/incy.png?width=1200&height=800&fit=crop)
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
![](https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600.png)
![](https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600.png)
![](/next-assets/images/schema-image-default.png)
Earnings Outlook For Incyte
October 30, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_4.png?width=1200&height=800&fit=crop)
Expert Ratings for Incyte
September 21, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.png?width=1200&height=800&fit=crop)
Analyst Ratings for Incyte
August 02, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Incyte's Earnings Outlook
July 31, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
![](https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715.png)
![](https://cdn.benzinga.com/files/images/story/2023/09/18/incy.png?width=1200&height=800&fit=crop)
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
September 18, 2023
Via Benzinga
Exposures
Product Safety
![](https://www.investors.com/wp-content/uploads/2018/09/stock-Incyte-01-shutter.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/08/01/incy.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/Cathie_Wood_Ark_Photo_courtesy_Benzinga_YouTube_and_Unsplash_19.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/07/24/sndx.png?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/07/19/jim_cramer_shutterstock2.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/07/12/incy.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/07/11/sndx.png?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/737536/gettyimages-1027139762.jpg)
![](https://talkmarkets.com/images/logos/talkmarkets.png)
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.